Epstein–Barr vaccine

Epstein–Barr vaccine

The Epstein–Barr vaccine is a vaccine against Epstein–Barr virus. The vaccine is not yet available,[1] but it is in clinical trials.[2][3][4] Gp350/220 is the primary target[5] and MVA-EL has been also proposed as a target.[6]

One challenge is that EBV expresses very different proteins during its lytic and its latent phases. To address this, vaccine candidates have been designed to include proteins from both phases.[7]

References